CN102159078B - 作为激酶抑制剂的化合物 - Google Patents
作为激酶抑制剂的化合物 Download PDFInfo
- Publication number
- CN102159078B CN102159078B CN200980129433.4A CN200980129433A CN102159078B CN 102159078 B CN102159078 B CN 102159078B CN 200980129433 A CN200980129433 A CN 200980129433A CN 102159078 B CN102159078 B CN 102159078B
- Authority
- CN
- China
- Prior art keywords
- oxygen base
- methoxyl group
- azaspiro
- heptan
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 Cc1cc2c(*)c(C)ccc2[n]1 Chemical compound Cc1cc2c(*)c(C)ccc2[n]1 0.000 description 8
- IDNDSWJMGOOVOJ-UHFFFAOYSA-N COc(c(CCCc1ccccc1)cc1ncc2)cc1c2Cl Chemical compound COc(c(CCCc1ccccc1)cc1ncc2)cc1c2Cl IDNDSWJMGOOVOJ-UHFFFAOYSA-N 0.000 description 1
- SBHOYAZAMNGYOA-UHFFFAOYSA-N Cc1c(cc(c(OCc2ccccc2)c2)OC)c2ncc1 Chemical compound Cc1c(cc(c(OCc2ccccc2)c2)OC)c2ncc1 SBHOYAZAMNGYOA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Abstract
Description
Claims (7)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8990808P | 2008-08-19 | 2008-08-19 | |
US61/089,908 | 2008-08-19 | ||
US12/540,300 US8211911B2 (en) | 2008-08-19 | 2009-08-12 | Compounds as kinase inhibitors |
US12/540,300 | 2009-08-12 | ||
PCT/US2009/053779 WO2010021918A1 (en) | 2008-08-19 | 2009-08-13 | Compounds as kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102159078A CN102159078A (zh) | 2011-08-17 |
CN102159078B true CN102159078B (zh) | 2014-05-21 |
Family
ID=41696956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980129433.4A Active CN102159078B (zh) | 2008-08-19 | 2009-08-13 | 作为激酶抑制剂的化合物 |
Country Status (13)
Country | Link |
---|---|
US (1) | US8211911B2 (zh) |
EP (1) | EP2312950B1 (zh) |
JP (1) | JP5585892B2 (zh) |
KR (1) | KR101727757B1 (zh) |
CN (1) | CN102159078B (zh) |
AU (1) | AU2009282962B2 (zh) |
BR (1) | BRPI0912475B8 (zh) |
CA (1) | CA2733250C (zh) |
ES (1) | ES2617678T3 (zh) |
IL (1) | IL210573A (zh) |
MX (1) | MX2010011813A (zh) |
NZ (1) | NZ590954A (zh) |
WO (1) | WO2010021918A1 (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2477723C2 (ru) | 2011-06-16 | 2013-03-20 | Общество С Ограниченной Ответственностью "Фьюжн Фарма" | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе |
WO2013148537A1 (en) * | 2012-03-29 | 2013-10-03 | Ning Xi | Substituted spirobicyclic compounds and methods of use |
WO2014127214A1 (en) | 2013-02-15 | 2014-08-21 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
CA2900680C (en) | 2013-02-20 | 2021-08-10 | Kala Pharmaceuticals, Inc. | Quinoline and quinazoline compounds and uses thereof for treating and/or preventing diseases |
MX355330B (es) | 2013-11-01 | 2018-04-16 | Kala Pharmaceuticals Inc | Formas cristalinas de compuestos terapeuticos y sus usos. |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
WO2018048747A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10336767B2 (en) | 2016-09-08 | 2019-07-02 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CN109748902B (zh) * | 2017-11-02 | 2020-11-06 | 杭州科巢生物科技有限公司 | 一种盐酸安罗替尼的制备方法 |
CN110357856B (zh) * | 2018-04-09 | 2021-02-26 | 新发药业有限公司 | 一种盐酸安罗替尼中间体及盐酸安罗替尼的制备方法 |
CN112469711A (zh) * | 2018-07-24 | 2021-03-09 | 正大天晴药业集团股份有限公司 | 一种喹啉衍生物的合成方法 |
CN108864050B (zh) * | 2018-07-25 | 2019-12-10 | 上海博璞诺科技发展有限公司 | 一种合成安罗替尼及其盐酸盐的方法 |
CN113045559B (zh) * | 2021-03-15 | 2022-05-20 | 贵州医科大学 | 一种二芳基脲类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用 |
US20230399313A1 (en) * | 2022-06-10 | 2023-12-14 | Advenchen Pharmaceuticals, LLC | Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4227989A1 (de) | 1992-08-21 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel |
US6143764A (en) | 1995-11-07 | 2000-11-07 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
JP3270834B2 (ja) * | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
PL205557B1 (pl) | 1999-02-10 | 2010-05-31 | Astrazeneca Ab | Pochodne indolu |
DE60126997T2 (de) | 2000-10-20 | 2007-10-25 | Eisai R&D Management Co., Ltd. | Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen |
AU2003257666A1 (en) | 2002-08-23 | 2004-03-11 | Kirin Beer Kabushiki Kaisha | COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME |
GB0318422D0 (en) * | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
CA2536788A1 (en) | 2003-08-29 | 2005-03-10 | Pfizer Inc. | Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents |
OA13349A (en) | 2003-12-23 | 2007-04-13 | Pfizer | Novel quinoline derivatives. |
EP1711495A2 (en) | 2004-01-23 | 2006-10-18 | Amgen Inc. | Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer |
BRPI0507373A (pt) * | 2004-01-23 | 2007-07-10 | Amgen Inc | compostos e método de uso |
JPWO2005080377A1 (ja) | 2004-02-20 | 2007-10-25 | キリンホールディングス株式会社 | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
WO2005097137A2 (en) | 2004-03-31 | 2005-10-20 | The Scripps Research Institute | Advanced quinazoline based protein kinase inhibitors |
WO2005114219A2 (en) | 2004-05-20 | 2005-12-01 | Wyeth | Assays to identify irreversibly binding inhibitors of receptor tyrosine kinases |
EP1915368A1 (en) | 2005-08-08 | 2008-04-30 | Pfizer, Inc. | Salts and polymorphs of a vergf-r inhibitor |
US7977346B2 (en) | 2006-01-17 | 2011-07-12 | Guoqing Paul Chen | Spiro compounds and methods of use |
US8148532B2 (en) | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
-
2009
- 2009-08-12 US US12/540,300 patent/US8211911B2/en active Active
- 2009-08-13 WO PCT/US2009/053779 patent/WO2010021918A1/en active Application Filing
- 2009-08-13 MX MX2010011813A patent/MX2010011813A/es active IP Right Grant
- 2009-08-13 JP JP2011523883A patent/JP5585892B2/ja active Active
- 2009-08-13 CN CN200980129433.4A patent/CN102159078B/zh active Active
- 2009-08-13 AU AU2009282962A patent/AU2009282962B2/en active Active
- 2009-08-13 ES ES09808627.5T patent/ES2617678T3/es active Active
- 2009-08-13 NZ NZ590954A patent/NZ590954A/xx not_active IP Right Cessation
- 2009-08-13 KR KR1020117002076A patent/KR101727757B1/ko active IP Right Grant
- 2009-08-13 BR BRPI0912475A patent/BRPI0912475B8/pt active IP Right Grant
- 2009-08-13 EP EP09808627.5A patent/EP2312950B1/en active Active
- 2009-08-13 CA CA2733250A patent/CA2733250C/en active Active
-
2011
- 2011-01-11 IL IL210573A patent/IL210573A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
BRPI0912475A8 (pt) | 2018-03-20 |
CA2733250C (en) | 2016-06-21 |
AU2009282962A8 (en) | 2011-11-10 |
BRPI0912475A2 (pt) | 2018-01-09 |
AU2009282962A1 (en) | 2010-02-25 |
CN102159078A (zh) | 2011-08-17 |
BRPI0912475B1 (pt) | 2020-12-29 |
KR20110044749A (ko) | 2011-04-29 |
JP5585892B2 (ja) | 2014-09-10 |
EP2312950B1 (en) | 2016-11-30 |
ES2617678T3 (es) | 2017-06-19 |
AU2009282962B2 (en) | 2015-10-08 |
NZ590954A (en) | 2012-11-30 |
JP2012500269A (ja) | 2012-01-05 |
CA2733250A1 (en) | 2010-02-25 |
EP2312950A4 (en) | 2012-10-24 |
IL210573A0 (en) | 2011-03-31 |
BRPI0912475B8 (pt) | 2021-05-25 |
WO2010021918A1 (en) | 2010-02-25 |
US20100048599A1 (en) | 2010-02-25 |
IL210573A (en) | 2016-05-31 |
US8211911B2 (en) | 2012-07-03 |
MX2010011813A (es) | 2010-12-01 |
WO2010021918A8 (en) | 2011-01-27 |
KR101727757B1 (ko) | 2017-04-17 |
EP2312950A1 (en) | 2011-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102159078B (zh) | 作为激酶抑制剂的化合物 | |
CN101809012B (zh) | 作为血管生成抑制剂的螺取代化合物 | |
CN101558055B (zh) | 作为血管生成抑制剂的螺取代化合物 | |
CN101431894B (zh) | 螺环化合物和应用方法 | |
EP2995618B1 (en) | [1,2,4]triazol [4,3-a]pyridine derivate, preparation method therefor or medical application thereof | |
WO2013170770A1 (zh) | 具有抗肿瘤活性的乙炔衍生物 | |
JP7323896B2 (ja) | カゼインキナーゼ1ε阻害剤、医薬組成物及びその使用 | |
KR20060009893A (ko) | Src 억제제와 조합된 항혈관형성제를 포함하는 치료제및 이것의 치료 용도 | |
CN107428762A (zh) | 酞嗪酮衍生物、其制备方法及用途 | |
WO2019196622A1 (zh) | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ADVENCHEN LAB LLC CHEN GUOQING NANJING AIDECHENG N Free format text: FORMER OWNER: ADVENCHEN LAB LLC CHEN GUOQING Effective date: 20140709 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140709 Address after: 210000 building 302, building A, incubator of medicine and biology, Nanjing hi tech Development Zone, Nanjing, Jiangsu Patentee after: Advenchen Laboratories, LLC Patentee after: Advenchen Laboratories LLC Patentee after: Chen Guoqing Patentee after: ADVENCHEN LABORATORIES NANJING LTD. Patentee after: ADVENCHEN PHARMACEUTICALS LLC Address before: 210000 building 302, building A, incubator of medicine and biology, Nanjing hi tech Development Zone, Nanjing, Jiangsu Patentee before: Advenchen Laboratories, LLC Patentee before: Advenchen Laboratories LLC Patentee before: Chen Guoqing |